CTLA4 and cancer: These results indicate that triple therapies may be effective in cancer therapy because oncolytic viruses reprogram the immunosuppressive TME, whereas immune checkpoint inhibitors such as anti‐CTLA4 and anti‐PD‐1/PD‐L1 antibodies hinder immune escape upon virotherapy.